Etanercept normalises left ventricular mass in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 881-887

  Daïen, Claire Immediato ^a,b   Fesler, Pierre ^c   Du Cailar, Guilhem ^c   Daïen, Vincent ^d   Mura, Thibault ^d,e   Dupuy, Anne Marie ^e   Cristol, Jean Paul ^c   Ribstein, Jean ^c   Combe, Bernard ^a,b   Morel, Jacques ^a,b  

^a UNIV MONTPELLIER   (France)

^b CNRS   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d GUI DE CHAULIAC HOSPITAL   (France)

^e HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; EARLY DIASTOLIC VELOCITY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; LONGITUDINAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOGLOBULIN G; ISOXAZOLES; METHOTREXATE; MIDDLE AGED; PULSE WAVE ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SULFASALAZINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS;

EID: 84877633753     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201489     Document Type: Article

References (57)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
2. Levy L, Fautrel B, Barnetche T, et al. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature. Clin Exp Rheumatol 2008;26:673-9.
3. Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006;54:60-7. (Pubitemid 43122187)
4. Corrao S, Salli L, Arnone S, et al. Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest 1996;26:293-7. (Pubitemid 26147064)
5. Corrao S, Scaglione R, Calvo L, et al. A meta-analysis of the effect size of rheumatoid arthritis on left ventricular mass: comment on the article by Rudominer et al. Arthritis Rheum 2009;60:2851-2.
6. Meune C, Wahbi K, Assous N, et al. Myocardial dysfunction in rheumatoid arthritis: a controlled tissue-Doppler echocardiography study. J Rheumatol 2007;34:2005-9. (Pubitemid 47548202)
7. Rudominer RL, Roman MJ, Devereux RB, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009;60:22-9.
8. Wislowska M, Jaszczyk B, Kochmanski M, et al. Diastolic heart function in RA patients. Rheumatol Int 2008;28:513-19. (Pubitemid 351422616)
9. Yazici D, Tokay S, Aydin S, et al. Echocardiographic evaluation of cardiac diastolic function in patients with rheumatoid arthritis: 5 years of follow-up. Clin Rheumatol 2008;27:647-50.
10. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004;33:231-8. (Pubitemid 38280822)
11. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6. (Pubitemid 20176696)
12. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-91. (Pubitemid 28182677)
13. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41. (Pubitemid 34163575)
14. Meaume S, Benetos A, Henry OF, et al. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001;21:2046-50. (Pubitemid 34219760)
15. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92. (Pubitemid 44386483)
16. Furst DE, Pangan AL, Harrold LR, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in disease course: results from the CORRONA registry. Arthritis Care Res; 2011 63:856-64.
17. van der Linden MP, Knevel R, Huizinga TW, et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011;63:37-42.
18. Halldin M, Fahlstadius P, de Faire U, et al. The metabolic syndrome and left ventricular hypertrophy - the influence of gender and physical activity. Blood Press 2012;21:153-60.
19. Villar AV, Llano M, Cobo M, et al. Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 2009;46:526-35.
20. Fesler P, Ribstein J, du Cailar G, et al. Determinants of cardiorenal damage progression in normotensive and never-treated hypertensive subjects. Kidney Int 2005;67:1974-9. (Pubitemid 40577734)
21. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-18. (Pubitemid 8066109)
22. du Cailar G, Fesler P, Ribstein J, et al. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension 2011;56:865-70.
23. Du Cailar G, Ribstein J, Daures JP, et al. Sodium and left ventricular mass in untreated hypertensive and normotensive subjects. Am J Physiol 1992;263:H177-81.
24. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
25. Naschitz JE, Gaitini L, Loewenstein L, et al. In-field validation of automatic blood pressure measuring devices. J Hum Hypertens 2000;14:37-42. (Pubitemid 30113629)
26. Wilkinson IB, Fuchs SA, Jansen IM, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998;16:2079-84. (Pubitemid 29002391)
27. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001;38:932-7. (Pubitemid 34258696)
28. Taillard V, Sardinoux M, Oudot C, et al. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy. Clin Endocrinol (Oxf) 2011;75:709-14.
29. Crowson CS, Myasoedova E, Davis JM III, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011;38:29-35.
30. Book C, Karlsson MK, Akesson K, et al. Early rheumatoid arthritis and body composition. Rheumatology (Oxford) 2009;48:1128-32.
31. Panoulas VF, Douglas KM, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1477-82. (Pubitemid 47317098)
32. Solomon DH, Curhan GC, Rimm EB, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004;50:3444-9. (Pubitemid 39488668)
33. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:366-8.
34. Dinh W, Futh R, Nickl W, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol 2009;8:58.
35. Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007;115:1398-407. (Pubitemid 46648375)
36. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65.
37. Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000;97:12746-51.
38. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001;104:826-31. (Pubitemid 32762683)
39. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8. (Pubitemid 16149701)
40. Sriramula S, Haque M, Majid DS, et al. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008;51:1345-51. (Pubitemid 351555948)
41. Puntmann VO, Taylor PC, Barr A, et al. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology (Oxford) 2010;49:528-35.
42. Hurd ER. Extraarticular manifestations of rheumatoid arthritis. Semin Arthritis Rheum 1979;8:151-76. (Pubitemid 9104121)
43. Pieretti J, Roman MJ, Devereux RB, et al. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007;116:419-26. (Pubitemid 47196547)
44. Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010;55:333-8.
45. Cypiene A, Laucevicius A, Venalis A, et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc 2007;50:119-22.
46. Angel K, Provan SA, Fagerhol MK, et al. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012;25:644-50.
47. Koldas L, Ayan F, Ikitimur B. Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Jpn Heart J 2003;44:693-704. (Pubitemid 41518970)
48. Schneider MP, Klingbeil AU, Delles C, et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension 2004;44:61-6. (Pubitemid 38823488)
49. Cuff-link. Lancet 1990;336:410.
50. Torre-Amione G, Wallace CK, Young JB, et al. The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy. Transplantation 2007;84:480-3. (Pubitemid 47312158)
51. Kotyla PJ, Owczarek A, Rakoczy J, et al. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol 2012;39:701-6.
52. Senel S, Cobankara V, Taskoylu O, et al. The safety and efficacy of etanercept on cardiac functions and lipid profile in patients with active rheumatoid arthritis. J Investig Med 2012;60:62-5.
53. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-6. (Pubitemid 39491919)
54. Solomon D, Harrold L, Rassen J. Cardiovascular risk reduction associated with TNF blockade: results from a large multi-site observational study. Arthritis Rheum 2011;63(Suppl 10):317.
55. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30. (Pubitemid 35284800)
56. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008;58:667-77. (Pubitemid 351364864)
57. Tomasson G, Aspelund T, Jonsson T, et al. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010;69:1649-54.